REGN•benzinga•
Regeneron And Sanofi Announce FDA Priority Review For Dupixent In Bullous Pemphigoid, With Approval Decision Expected By June 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 18, 2025 by benzinga